HOME >> BIOLOGY >> NEWS
Gladstone investigator Mike McCune wins prestigious NIH Director's Pioneer Award

Joseph ("Mike") McCune, MD, PhD, a senior investigator at the Gladstone Institute of Virology and Immunology and a professor of medicine and of microbiology and immunology at the University of California, San Francisco (UCSF), was today named a recipient of the first-ever NIH Director's Pioneer Award.

McCune is among nine researchers across the country chosen to receive the prestigious award, established last year and awarded for the first time this year. The NIH Director's Pioneer Award (NDPA) program was created to identify and fund investigators of exceptionally creative abilities and to provide them with enough funding -- $500,000 per year in direct costs over five years -- to develop and test far-ranging ideas. The only constraint on the funding is that it be used for research that is relevant to the NIH mission of science in pursuit of knowledge about the nature and behavior of living systems.

McCune will use the funds to further his research into the mechanisms by which HIV causes immunodeficiency, with an eye toward understanding immune responses that might prevent the development of AIDS in HIV-infected people. Such insight, he says, could lead to more effective therapeutics for those with HIV, as well as to effective vaccine strategies for those at risk of being infected with HIV.

In recent years, McCune and his Gladstone team have focused on disease-causing mechanisms of HIV infection in research mice. They have also studied HIV effects on the production of disease-fighting white blood cells in patients with HIV disease. This work has provided insights into the mechanisms that normally support the human immune system and the processes by which HIV can cause immunodeficiency.

"Now I want to know if there are certain types of immune responses that protect against infection and others that might instead slow down the pace of disease," he explains. "Perhaps more importantly, I want to apply this knowledge to the creati
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-476-2557
University of California - San Francisco
29-Sep-2004


Page: 1 2

Related biology news :

1. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
2. Gladstone study reveals how genetic factor may increase risk for Alzheimers disease
3. Gladstone researchers find method to study hidden HIV reservoirs
4. New Gladstone/UCSF study finds inhibiting fat synthesis results in obesity resistance in mice
5. Gladstone/UCSF team discovers interaction of two brain proteins may be key factor in development of Alzheimers disease
6. AIDS Virus May Evolve Differently In Cerebrospinal Fluid Compared With Blood In Some Patients, UCSF/Gladstone Research Finds
7. UCSF/Gladstone Finding May Explain HIVS Ability To Infect Cells Lacking The Key Target Of HIV: The CD4 Receptor
8. Breakthrough In Understanding The Biology Of Fat-- UCSF/Gladstone Scientists Discover Gene For Key Enzyme
9. AIUM recognizes new investigators in ultrasound
10. Principal investigators named for international scholars in breast cancer research program
11. Columbia investigators win 2003 Gairdner International Award for research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... A firm ... to The Leukemia & Lymphoma Society (LLS). This donation will help fund not only ... patients and their families. , “We are always on the lookout for ways ...
(Date:3/9/2019)... ... March 09, 2019 , ... ... hM4Di ligands – exciting compounds for scientists studying GPCR and DREADD signalling. Hello ... and the National Institute of Neurological Disorders and Stroke, both institutes of the ...
(Date:2/27/2019)... ... 2019 , ... Fluxion Biosciences, a leading developer of precision solutions for life ... grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant ... Dr. Omar Mian at the Cleveland Clinic. , Liquid biopsies offer the potential to ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... ... solution for preclinical research organizations. It is a low code, GDPR/21 CFR ... and facilities, innovative technology-driven automated data capture and seamless data and information ...
(Date:3/11/2019)... ... , ... USDM Life Sciences and Generis have partnered ... GxP compliance for the life sciences industry. USDM Cloud Assurance delivers a ... for Generis’ flagship product, CARA. , Presentation One:, What: Cloud ...
(Date:3/5/2019)... ... March 05, 2019 , ... Modality Solutions, ... with regulatory filing authorities, logistics network experts, and experienced integrated staffing professionals. ... in the Inc. Verified Profile program, Inc. editors independently reviewed the Houston-based cold ...
(Date:2/26/2019)... ... February 26, 2019 , ... The idea for ... Villani developed the Visikol® tissue clearing technology for improved tissue characterization. From this ... products focused company to primarily a services focused company. , Today, Visikol ...
Breaking Biology Technology:
Cached News: